Drug Details
General Information of the Drug (ID: DR5851) | ||||
---|---|---|---|---|
Name |
Dasatinib
|
|||
Synonyms |
Sprycel (TN); BMS 354825; BMS-354825; BMS-354825, Sprycel, BMS354825, Dasatinib; BMS354825; Dasatinib (USAN); Dasatinib [USAN]; Dasatinib anhydrous; Dasatinib, BMS 354825; Dasatinibum; Sprycel; Spyrcel
Click to Show/Hide
|
|||
Molecular Type |
Small molecule
|
|||
Disease | Chronic myelogenous leukaemia [ICD-11: 2A20] | Approved | [1] | |
Structure |
Click to Download Mol2D MOL |
|||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
Formula |
C22H26ClN7O2S
|
|||
PubChem CID | ||||
Canonical SMILES |
CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO
|
|||
InChI |
1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)
|
|||
InChIKey |
ZBNZXTGUTAYRHI-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 302962-49-8
|
|||
ChEBI ID | ||||
GDSC | ||||
TTD Drug ID | ||||
DrugBank ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
Arsenic trioxide | Realgar and orpiment | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | ATF-4 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Phosphorylation | ATF2 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | BBC3 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | CASP9 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Phosphorylation | JNK1 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Phosphorylation | JUN | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | SUP-B15 | CVCL_0103 | B acute lymphoblastic leukemia | Homo sapiens | ||
TOM-1 | CVCL_1895 | B acute lymphoblastic leukemia | Homo sapiens | |||
Experimental
Result(s) |
Combining ATO and Dasatinib leads to severe cell apoptosis by activating the UPR apoptotic IRE1/JNK/PUMA axis, while neutralizing the UPR ATF4-dependent anti-apoptotic axis, activated by ATO alone. | |||||
β. A List of Natural Product(s) Able to Decrease the Adverse Effect of This Drug | ||||||
Curcumin | Hellenia speciosa | Click to Show/Hide the Molecular Data of This NP | ||||
Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [3] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
In-vitro Model | HCT 116 | CVCL_0291 | Colon carcinoma | Homo sapiens | ||
HT-29 | CVCL_0320 | Colon adenocarcinoma | Homo sapiens | |||
Experimental
Result(s) |
The combinatorial therapy inhibited cellular growth, invasion and colonosphere formation and also reduced CSC population as evidenced by the decreased expression of CSC specific markers: CD133, CD44, CD166 and ALDH. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Fusion protein Bcr-Abl (Bcr-Abl) | Molecule Info | [4] | |
Fyn tyrosine protein kinase (FYN) | Molecule Info | [4] | ||
LCK tyrosine protein kinase (LCK) | Molecule Info | [4] | ||
Proto-oncogene c-Src (SRC) | Molecule Info | [4] | ||
KEGG Pathway | ErbB signaling pathway | Click to Show/Hide | ||
2 | Rap1 signaling pathway | |||
3 | Chemokine signaling pathway | |||
4 | Endocytosis | |||
5 | VEGF signaling pathway | |||
6 | Focal adhesion | |||
7 | Adherens junction | |||
8 | Tight junction | |||
9 | Gap junction | |||
10 | Platelet activation | |||
11 | GABAergic synapse | |||
12 | Inflammatory mediator regulation of TRP channels | |||
13 | Regulation of actin cytoskeleton | |||
14 | GnRH signaling pathway | |||
15 | Estrogen signaling pathway | |||
16 | Prolactin signaling pathway | |||
17 | Thyroid hormone signaling pathway | |||
18 | Oxytocin signaling pathway | |||
19 | Bacterial invasion of epithelial cells | |||
20 | Epithelial cell signaling in Helicobacter pylori infection | |||
21 | Shigellosis | |||
22 | Tuberculosis | |||
23 | Hepatitis B | |||
24 | Viral carcinogenesis | |||
25 | Proteoglycans in cancer | |||
26 | Sphingolipid signaling pathway | |||
27 | Axon guidance | |||
28 | Osteoclast differentiation | |||
29 | Natural killer cell mediated cytotoxicity | |||
30 | T cell receptor signaling pathway | |||
31 | Fc epsilon RI signaling pathway | |||
32 | Cholinergic synapse | |||
33 | Prion diseases | |||
34 | Pathogenic Escherichia coli infection | |||
35 | Measles | |||
36 | Viral myocarditis | |||
37 | NF-kappa B signaling pathway | |||
38 | HTLV-I infection | |||
39 | Primary immunodeficiency | |||
NetPath Pathway | IL2 Signaling Pathway | Click to Show/Hide | ||
2 | TSH Signaling Pathway | |||
3 | TGF_beta_Receptor Signaling Pathway | |||
4 | TCR Signaling Pathway | |||
Panther Pathway | Angiogenesis | Click to Show/Hide | ||
2 | Cadherin signaling pathway | |||
3 | Integrin signalling pathway | |||
4 | Parkinson disease | |||
5 | CCKR signaling map ST | |||
6 | Axon guidance mediated by semaphorins | |||
7 | T cell activation | |||
Pathwhiz Pathway | Fc Epsilon Receptor I Signaling in Mast Cells | Click to Show/Hide | ||
Pathway Interaction Database | Endothelins | Click to Show/Hide | ||
2 | Signaling events mediated by PRL | |||
3 | LPA receptor mediated events | |||
4 | Atypical NF-kappaB pathway | |||
5 | Glypican 1 network | |||
6 | Plasma membrane estrogen receptor signaling | |||
7 | Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) | |||
8 | Signaling events mediated by PTP1B | |||
9 | S1P3 pathway | |||
10 | EPHB forward signaling | |||
11 | Nectin adhesion pathway | |||
12 | Regulation of p38-alpha and p38-beta | |||
13 | CDC42 signaling events | |||
14 | Signaling events regulated by Ret tyrosine kinase | |||
15 | Arf6 signaling events | |||
16 | Signaling events mediated by TCPTP | |||
17 | FAS (CD95) signaling pathway | |||
18 | Thromboxane A2 receptor signaling | |||
19 | Netrin-mediated signaling events | |||
20 | Alpha9 beta1 integrin signaling events | |||
21 | CXCR4-mediated signaling events | |||
22 | EGF receptor (ErbB1) signaling pathway | |||
23 | Class I PI3K signaling events | |||
24 | Posttranslational regulation of adherens junction stability and dissassembly | |||
25 | Regulation of Androgen receptor activity | |||
26 | E-cadherin signaling in the nascent adherens junction | |||
27 | amb2 Integrin signaling | |||
28 | Integrins in angiogenesis | |||
29 | ErbB1 downstream signaling | |||
30 | Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | |||
31 | ErbB2/ErbB3 signaling events | |||
32 | EPHA forward signaling | |||
33 | E-cadherin signaling in keratinocytes | |||
34 | PDGFR-beta signaling pathway | |||
35 | Nongenotropic Androgen signaling | |||
36 | Internalization of ErbB1 | |||
37 | CXCR3-mediated signaling events | |||
38 | Signaling events mediated by VEGFR1 and VEGFR2 | |||
39 | Syndecan-2-mediated signaling events | |||
40 | Class I PI3K signaling events mediated by Akt | |||
41 | Syndecan-3-mediated signaling events | |||
42 | Ephrin B reverse signaling | |||
43 | Trk receptor signaling mediated by PI3K and PLC-gamma | |||
44 | EPHA2 forward signaling | |||
45 | Alpha-synuclein signaling | |||
46 | FGF signaling pathway | |||
47 | Alpha4 beta1 integrin signaling events | |||
48 | Signaling events mediated by focal adhesion kinase | |||
49 | Fc-epsilon receptor I signaling in mast cells | |||
50 | ErbB4 signaling events | |||
51 | TCR signaling in naï | |||
52 | ||||
53 | Ephrin A reverse signaling | |||
54 | Reelin signaling pathway | |||
55 | TCR signaling in naï | |||
56 | ||||
57 | Angiopoietin receptor Tie2-mediated signaling | |||
58 | IL2-mediated signaling events | |||
59 | Nephrin/Neph1 signaling in the kidney podocyte | |||
60 | IL12-mediated signaling events | |||
61 | SHP2 signaling | |||
62 | IL2 signaling events mediated by PI3K | |||
63 | IL2 signaling events mediated by STAT5 | |||
Reactome | GPVI-mediated activation cascade | Click to Show/Hide | ||
2 | PIP3 activates AKT signaling | |||
3 | Regulation of KIT signaling | |||
4 | Cell surface interactions at the vascular wall | |||
5 | FCGR activation | |||
6 | PECAM1 interactions | |||
7 | Constitutive Signaling by Aberrant PI3K in Cancer | |||
8 | DAP12 signaling | |||
9 | EPH-Ephrin signaling | |||
10 | Role of LAT2/NTAL/LAB on calcium mobilization | |||
11 | Nephrin interactions | |||
12 | NCAM signaling for neurite out-growth | |||
13 | CD28 co-stimulation | |||
14 | CD28 dependent PI3K/Akt signaling | |||
15 | CD28 dependent Vav1 pathway | |||
16 | CTLA4 inhibitory signaling | |||
17 | EPHB-mediated forward signaling | |||
18 | EPHA-mediated growth cone collapse | |||
19 | EPH-ephrin mediated repulsion of cells | |||
20 | CRMPs in Sema3A signaling | |||
21 | DCC mediated attractive signaling | |||
22 | Netrin mediated repulsion signals | |||
23 | VEGFA-VEGFR2 Pathway | |||
24 | Dectin-2 family | |||
25 | CD209 (DC-SIGN) signaling | |||
26 | RAF/MAP kinase cascade | |||
27 | Platelet Adhesion to exposed collagen | |||
28 | Regulation of signaling by CBL | |||
29 | Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | |||
30 | Phosphorylation of CD3 and TCR zeta chains | |||
31 | Translocation of ZAP-70 to Immunological synapse | |||
32 | Generation of second messenger molecules | |||
33 | PD-1 signaling | |||
34 | Interleukin-2 signaling | |||
WikiPathways | ErbB Signaling Pathway | Click to Show/Hide | ||
2 | Senescence and Autophagy in Cancer | |||
3 | Notch Signaling Pathway | |||
4 | EPO Receptor Signaling | |||
5 | EGF/EGFR Signaling Pathway | |||
6 | TGF beta Signaling Pathway | |||
7 | Signaling of Hepatocyte Growth Factor Receptor | |||
8 | Kit receptor signaling pathway | |||
9 | Pregnane X Receptor pathway | |||
10 | Aryl Hydrocarbon Receptor Pathway | |||
11 | IL-3 Signaling Pathway | |||
12 | Nanoparticle-mediated activation of receptor signaling | |||
13 | Polycystic Kidney Disease Pathway | |||
14 | Alpha 6 Beta 4 signaling pathway | |||
15 | BDNF signaling pathway | |||
16 | Integrated Pancreatic Cancer Pathway | |||
17 | Oncostatin M Signaling Pathway | |||
18 | Interleukin-11 Signaling Pathway | |||
19 | AGE/RAGE pathway | |||
20 | Signaling Pathways in Glioblastoma | |||
21 | TSLP Signaling Pathway | |||
22 | Arylhydrocarbon receptor (AhR) signaling pathway | |||
23 | Regulation of Microtubule Cytoskeleton | |||
24 | FSH signaling pathway | |||
25 | Leptin signaling pathway | |||
26 | RANKL/RANK Signaling Pathway | |||
27 | Integrin-mediated Cell Adhesion | |||
28 | Angiogenesis | |||
29 | Androgen receptor signaling pathway | |||
30 | TCR Signaling Pathway | |||
31 | Interferon type I signaling pathways | |||
32 | IL-2 Signaling Pathway | |||
33 | Ectoderm Differentiation | |||
34 | Fc epsilon receptor (FCERI) signaling | |||
35 | Signaling by the B Cell Receptor (BCR) | |||
36 | Signaling by SCF-KIT | |||
37 | DAP12 interactions | |||
38 | Host Interactions of HIV factors | |||
39 | PIP3 activates AKT signaling | |||
40 | T-Cell Receptor and Co-stimulatory Signaling | |||
41 | Primary Focal Segmental Glomerulosclerosis FSGS | |||
42 | B Cell Receptor Signaling Pathway | |||
43 | Pathogenic Escherichia coli infection | |||
44 | IL-7 Signaling Pathway | |||
45 | Semaphorin interactions | |||
46 | Platelet Adhesion to exposed collagen | |||
47 | Netrin-1 signaling | |||
48 | Nephrin interactions | |||
49 | NCAM signaling for neurite out-growth | |||
50 | GPVI-mediated activation cascade | |||
51 | Costimulation by the CD28 family | |||
52 | Cell surface interactions at the vascular wall | |||
53 | Inflammatory Response Pathway | |||
54 | TCR signaling |